{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:00:35Z","timestamp":1772452835224,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Due to demographic shifts, the population is aging, and patients are experiencing more comorbidities. Stereotactic body radiotherapy (SBRT) offers high rates of local control for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC). However, obtaining histopathological confirmation can be challenging due to severe comorbidities, small tumors, or unfavorable anatomical locations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between 2011 and 2022, we retrospectively analyzed a\u00a0cohort of patients who underwent lung SBRT for presumed early-stage NSCLC at our institution. Out of 486 consecutive patients treated during this period, 56\u00a0patients (11.5%) with a\u00a0total of 61\u00a0lesions were identified and included in this retrospective study. All included patients lacked histopathological confirmation prior to treatment and had no evidence of other active malignancies. The primary objective of this analysis was to evaluate pulmonary function tests before and after SBRT, including long-term follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median overall survival (OS) after empiric SBRT was 50.7 months (95% confidence interval [CI] 12.8\u201388.7). Survival rates at 1\u00a0year and 2\u00a0years were 88.4 and 71.1%, respectively. The 1\u2011, 2\u2011 and 3\u2011year local control rates were 96.6%, 92.3% and 87.1%. Pulmonary function tests indicated a\u00a0relative increase in the mean forced expiratory volume in 1\u202fs (FEV1) of 0.55% (SD 13.5) and 2.0% (SD: 20.0) at 6 and 12\u00a0months, respectively. In contrast, the mean diffusing capacity of the lungs for carbon monoxide (DLCO) showed a\u00a0relative decline of 7.4% (SD 16.6) and 6.3% (SD 26.1) at 6\u00a0and 12\u00a0months, respectively. Patients with lower comorbidity scores (CCI \u2264\u202f5) exhibited significantly improved OS (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.011). Long-term oxygen therapy (LTOT) prior to SBRT was associated with shorter OS (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.02) and a\u00a0relatively high incidence of grade\u00a02\u20133 pulmonary disorders. Chronic obstructive pulmonary disease (COPD) was identified as a\u00a0possible risk factor for severe treatment-related toxicity. Notably, all patients who experienced grade\u00a03 pulmonary disorders required LTOT before SBRT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Empiric SBRT is a\u00a0safe and effective treatment for presumed early-stage NSCLC in patients without histopathological confirmation. Even in patients requiring oxygen therapy and with severe comorbidities, long-term survival is feasible with acceptable treatment-related toxicity. Optimal dose fractionation and biologically effective dose (BED) levels for frail patients without histological confirmation remain undefined. Prospective trials are warranted to determine the most effective and safe SBRT regimens for this vulnerable patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00066-025-02434-8","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T17:47:00Z","timestamp":1754329620000},"page":"289-298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Empiric stereotactic body radiotherapy for presumed early-stage lung cancer"],"prefix":"10.1007","volume":"202","author":[{"given":"Esra","family":"Degerli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"El-Marouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6260-5249","authenticated-orcid":false,"given":"Lukas","family":"K\u00e4smann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khulangaa","family":"Khaltar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sina","family":"Mansoorian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cedric","family":"Richlitzki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Kauffmann-Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Tufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Reinmuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Duell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina-Sophie","family":"Schmidt-Hegemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farkhad","family":"Manapov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chukwuka","family":"Eze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"2434_CR1","doi-asserted-by":"publisher","first-page":"234S","DOI":"10.1378\/chest.07-1378","volume-title":"Treatment of non-small cell lung cancer stage\u00a0I and stage\u00a0II: ACCP evidence-based clinical practice guidelines","author":"WJ Scott","year":"2007","unstructured":"Scott\u00a0WJ, Howington\u00a0J, Feigenberg\u00a0S, Movsas\u00a0B, Pisters\u00a0K, American College of Chest Physicians (2007) Treatment of non-small cell lung cancer stage\u00a0I and stage\u00a0II: ACCP evidence-based clinical practice guidelines, 2nd\u00a0edn. vol 132, pp\u00a0234S\u2013242S https:\/\/doi.org\/10.1378\/chest.07-1378","edition":"2"},{"key":"2434_CR2","first-page":"100736","volume":"45","author":"S Hering","year":"2024","unstructured":"Hering\u00a0S, Nieto\u00a0A, Marschner\u00a0S, Hofmaier\u00a0J, Schmidt-Hegemann\u00a0N\u2011S, da Silva Mendes\u00a0V, Landry\u00a0G, Niyazi\u00a0M, Manapov\u00a0F, Belka\u00a0C (2024) The role of online MR-guided multi-fraction stereotactic ablative radiotherapy in lung tumours. Clin Transl Radiat Oncol 45:100736","journal-title":"Clin Transl Radiat Oncol"},{"key":"2434_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ijrobp.2007.10.053","volume":"70","author":"FJ Lagerwaard","year":"2008","unstructured":"Lagerwaard\u00a0FJ, Haasbeek\u00a0CJA, Smit\u00a0EF, Slotman\u00a0BJ, Senan\u00a0S (2008) Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage\u00a0I Non\u2013Small-Cell Lung Cancer. Int J Radiat Oncol 70:685\u2013692. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.10.053","journal-title":"Int J Radiat Oncol"},{"key":"2434_CR4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ijrobp.2009.05.004","volume":"77","author":"GMM Videtic","year":"2010","unstructured":"Videtic\u00a0GMM, Stephans\u00a0K, Reddy\u00a0C, Gajdos\u00a0S, Kolar\u00a0M, Clouser\u00a0E, Djemil\u00a0T (2010) Intensity-Modulated Radiotherapy\u2013Based Stereotactic Body Radiotherapy for Medically Inoperable Early-Stage Lung Cancer: Excellent Local Control. Int J Radiat Oncol 77:344\u2013349. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.05.004","journal-title":"Int J Radiat Oncol"},{"key":"2434_CR5","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.ijrobp.2010.06.040","volume":"81","author":"AV Louie","year":"2011","unstructured":"Louie\u00a0AV, Rodrigues\u00a0G, Hannouf\u00a0M, Zaric\u00a0GS, Palma\u00a0DA, Cao\u00a0JQ, Yaremko\u00a0BP, Malthaner\u00a0R, Mocanu\u00a0JD (2011) Stereotactic Body Radiotherapy Versus Surgery for Medically Operable Stage\u00a0I Non\u2013Small-Cell Lung Cancer: A\u00a0Markov Model\u2013Based Decision Analysis. Int J Radiat Oncol 81:964\u2013973. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.06.040","journal-title":"Int J Radiat Oncol"},{"key":"2434_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2016.08.015","volume":"121","author":"J Nyman","year":"2016","unstructured":"Nyman\u00a0J, Hallqvist\u00a0A, Lund\u00a0J\u2011\u00c5, Brustugun\u00a0O\u2011T, Bergman\u00a0B, Bergstr\u00f6m\u00a0P, Friesland\u00a0S, Lewensohn\u00a0R, Holmberg\u00a0E, Lax\u00a0I (2016) SPACE\u2014a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage\u00a0I NSCLC. Radiother Oncol 121:1\u20138","journal-title":"Radiother Oncol"},{"key":"2434_CR7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","volume":"20","author":"D Ball","year":"2019","unstructured":"Ball\u00a0D, Mai\u00a0GT, Vinod\u00a0S, Babington\u00a0S, Ruben\u00a0J, Kron\u00a0T, Chesson\u00a0B, Herschtal\u00a0A, Vanevski\u00a0M, Rezo\u00a0A (2019) Stereotactic ablative radiotherapy versus standard radiotherapy in stage\u00a01 non-small-cell lung cancer (TROG 09.02 CHISEL): a\u00a0phase\u00a03, open-label, randomised controlled trial. Lancet Oncol 20:494\u2013503","journal-title":"Lancet Oncol"},{"key":"2434_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1053\/j.seminoncol.2018.06.002","volume":"45","author":"A Shinde","year":"2018","unstructured":"Shinde\u00a0A, Li\u00a0R, Kim\u00a0J, Salgia\u00a0R, Hurria\u00a0A, Amini\u00a0A (2018) Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly. Seminars Oncol 45:210\u2013219. https:\/\/doi.org\/10.1053\/j.seminoncol.2018.06.002","journal-title":"Seminars Oncol"},{"key":"2434_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.21037\/tlcr.2018.12.12","volume":"8","author":"AT Berman","year":"2019","unstructured":"Berman\u00a0AT, Jabbour\u00a0SK, Vachani\u00a0A, Robinson\u00a0C, Choi\u00a0JI, Mohindra\u00a0P, Rengan\u00a0R, Bradley\u00a0J, Simone\u00a0CB (2019) Empiric Radiotherapy for Lung Cancer Collaborative Group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation. Transl Lung Cancer Res 8:5\u201314. https:\/\/doi.org\/10.21037\/tlcr.2018.12.12","journal-title":"Transl Lung Cancer Res"},{"key":"2434_CR10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/1759-7714.12635","volume":"9","author":"S Hasan","year":"2018","unstructured":"Hasan\u00a0S, Colonias\u00a0A, Mickus\u00a0T, VanDeusen\u00a0M, Wegner\u00a0RE (2018) Image-based management of empiric lung stereotactic body radiotherapy (SBRT) without biopsy: Predictors from a\u00a010-year single institution experience. Thorac Cancer 9:699\u2013706. https:\/\/doi.org\/10.1111\/1759-7714.12635","journal-title":"Thorac Cancer"},{"key":"2434_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00408-013-9500-6","volume":"191","author":"YT Sim","year":"2013","unstructured":"Sim\u00a0YT, Goh\u00a0YG, Dempsey\u00a0MF, Han\u00a0S, Poon\u00a0FW (2013) PET\u2013CT Evaluation of Solitary Pulmonary Nodules: Correlation with Maximum Standardized Uptake Value and Pathology. Am J Physiol 191:625\u2013632. https:\/\/doi.org\/10.1007\/s00408-013-9500-6","journal-title":"Am J Physiol"},{"key":"2434_CR12","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","volume":"16","author":"JY Chang","year":"2015","unstructured":"Chang\u00a0JY, Senan\u00a0S, Paul\u00a0MA, Mehran\u00a0RJ, Louie\u00a0AV, Balter\u00a0P, Groen\u00a0HJ, McRae\u00a0SE, Widder\u00a0J, Feng\u00a0L (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage\u00a0I non-small-cell lung cancer: a\u00a0pooled analysis of two randomised trials. Lancet Oncol 16:630\u2013637","journal-title":"Lancet Oncol"},{"key":"2434_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ijrobp.2009.06.091","volume":"76","author":"LB Marks","year":"2010","unstructured":"Marks\u00a0LB, Bentzen\u00a0SM, Deasy\u00a0JO, F\u2011MS KBJD, Vogelius\u00a0IS, El Naqa\u00a0I, Hubbs\u00a0JL, Lebesque\u00a0JV, Timmerman\u00a0RD, Martel\u00a0MK, Jackson\u00a0A (2010) Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 76:70\u201376. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.06.091","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2434_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-2-21","author":"H Yamashita","year":"2007","unstructured":"Yamashita\u00a0H, Nakagawa\u00a0K, Nakamura\u00a0N, Koyanagi\u00a0H, Tago\u00a0M, Igaki\u00a0H, Shiraishi\u00a0K, Sasano\u00a0N, Ohtomo\u00a0K (2007) Exceptionally high incidence of symptomatic grade\u00a02\u20135 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol. https:\/\/doi.org\/10.1186\/1748-717X-2-21","journal-title":"Radiat Oncol"},{"key":"2434_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00428-017-2276-y","volume":"472","author":"L Bertero","year":"2018","unstructured":"Bertero\u00a0L, Massa\u00a0F, Metovic\u00a0J, Zanetti\u00a0R, Castellano\u00a0I, Ricardi\u00a0U, Papotti\u00a0M, Cassoni\u00a0P (2018) Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why? Virchows Arch 472:519\u2013531. https:\/\/doi.org\/10.1007\/s00428-017-2276-y","journal-title":"Virchows Arch"},{"key":"2434_CR16","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/archinte.1997.00440290031002","volume":"157","author":"SJ Swensen","year":"1997","unstructured":"Swensen\u00a0SJ, Silverstein\u00a0MD, Ilstrup\u00a0DM, Schleck\u00a0CD, Edell\u00a0ES (1997) The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med 157:849\u2013855","journal-title":"Arch Intern Med"},{"key":"2434_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4103\/2231-0770.90915","volume":"1","author":"AN Khan","year":"2011","unstructured":"Khan\u00a0AN, Al-Jahdali\u00a0HH, Irion\u00a0KL, Arabi\u00a0M, Koteyar\u00a0SS (2011) Solitary pulmonary nodule: A\u00a0diagnostic algorithm in the light of current imaging technique. Avicenna J Med 1:39\u201351. https:\/\/doi.org\/10.4103\/2231-0770.90915","journal-title":"Avicenna J Med"},{"key":"2434_CR18","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray\u00a0F, Laversanne\u00a0M, Sung\u00a0H, Ferlay\u00a0J, Siegel\u00a0RL, Soerjomataram\u00a0I, Jemal\u00a0A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca: A Cancer J Clin 74:229\u2013263","journal-title":"Ca: A Cancer J Clin"},{"key":"2434_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-024-02276-w","author":"J Ohlinger","year":"2024","unstructured":"Ohlinger\u00a0J, Vordermark\u00a0D, Ostheimer\u00a0C, Bache\u00a0M, Tzschoppe\u00a0T, Demircan\u00a0K, Schomburg\u00a0L, Medenwald\u00a0D, Seliger\u00a0B (2024) Change in the serum selenium level of patients with non-metastatic and metastatic non-small cell lung cancer (NSCLC) during radiotherapy as a\u00a0predictive factor for survival. Strahlenther Onkol. https:\/\/doi.org\/10.1007\/s00066-024-02276-w","journal-title":"Strahlenther Onkol"},{"key":"2434_CR20","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","volume":"32","author":"J Remon","year":"2021","unstructured":"Remon\u00a0J, Soria\u00a0J\u2011C, Peters\u00a0S (2021) Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol 32:1637\u20131642","journal-title":"Ann Oncol"},{"key":"2434_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-024-02339-y","author":"MT Yilmaz","year":"2024","unstructured":"Yilmaz\u00a0MT, Hurmuz\u00a0P, Gurlek\u00a0E, Yildiz\u00a0D, Cengiz\u00a0M (2024) Evaluating the impact of cardiac substructure dosimetric parameters on survival in lung cancer patients undergoing postoperative radiotherapy. Strahlenther Onkol. https:\/\/doi.org\/10.1007\/s00066-024-02339-y","journal-title":"Strahlenther Onkol"},{"key":"2434_CR22","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.21037\/tlcr-23-180","volume":"12","author":"Y Guo","year":"2023","unstructured":"Guo\u00a0Y, Zhu\u00a0Y, Zhang\u00a0R, Yang\u00a0S, Kepka\u00a0L, Viani\u00a0GA, Milano\u00a0MT, Sio\u00a0TT, Sun\u00a0X, Wu\u00a0H (2023) Five-year follow-up after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer: a\u00a0multicenter study. Transl Lung Cancer Res 12:1293","journal-title":"Transl Lung Cancer Res"},{"key":"2434_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-024-02328-1","author":"G Ugurluer","year":"2024","unstructured":"Ugurluer\u00a0G, Dincer\u00a0N, Mustafayev\u00a0TZ, Gungor\u00a0G, Abacioglu\u00a0MU, Sengoz\u00a0M, Ozyar\u00a0E, Atalar\u00a0B (2024) MR-guided online adaptive stereotactic body radiotherapy (MRgSBRT) of primary lung tumors and lung oligometastases. Strahlenther Onkol. https:\/\/doi.org\/10.1007\/s00066-024-02328-1","journal-title":"Strahlenther Onkol"},{"key":"2434_CR24","doi-asserted-by":"crossref","unstructured":"Wegner\u00a0RE, Ahmed\u00a0N, Hasan\u00a0S, Schumacher\u00a0LY, Van Deusen\u00a0M, Colonias\u00a0A (2018) SBRT for early stage lung cancer: outcomes from biopsy-proven and empirically treated lesions. Lung Cancer Manag 7:","DOI":"10.2217\/lmt-2018-0006"},{"key":"2434_CR25","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00066-024-02260-4","volume":"200","author":"S Wegen","year":"2024","unstructured":"Wegen\u00a0S, Nestle\u00a0U, Zamboglou\u00a0C, Spohn\u00a0SKB, Nicolay\u00a0NH, Unterrainer\u00a0LM, Koerber\u00a0SA, La Foug\u00e8re\u00a0C, Fokas\u00a0E, Kobe\u00a0C, Eze\u00a0C, Grosu\u00a0AL, Fendler\u00a0WP, Holzgreve\u00a0A, Werner\u00a0R, Schmidt-Hegemann\u00a0NS (2024) Implementation of PET\/CT in radiation oncology\u2014a patterns-of-care analysis of the German Society of Nuclear Medicine and the German Society of Radiation Oncology. Strahlenther Onkol 200:931\u2013941. https:\/\/doi.org\/10.1007\/s00066-024-02260-4","journal-title":"Strahlenther Onkol"},{"key":"2434_CR26","first-page":"390","volume":"85","author":"CE Rutter","year":"2014","unstructured":"Rutter\u00a0CE, Corso\u00a0CD, Park\u00a0HS, Mancini\u00a0BR, Yeboa\u00a0DN, Lester-Coll\u00a0NH, Kim\u00a0AW, Decker\u00a0RH (2014) Increase in the use of lung stereotactic body radiotherapy without a\u00a0preceding biopsy in the United States. Cancer Treat Res 85:390\u2013394","journal-title":"Cancer Treat Res"},{"key":"2434_CR27","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.radonc.2011.09.017","volume":"101","author":"NE Verstegen","year":"2011","unstructured":"Verstegen\u00a0NE, Lagerwaard\u00a0FJ, Haasbeek\u00a0CJ, Slotman\u00a0BJ, Senan\u00a0S (2011) Outcomes of stereotactic ablative radiotherapy following a\u00a0clinical diagnosis of stage\u00a0I NSCLC: comparison with a\u00a0contemporaneous cohort with pathologically proven disease. Radiother Oncol 101:250\u2013254","journal-title":"Radiother Oncol"},{"key":"2434_CR28","doi-asserted-by":"publisher","first-page":"100707","DOI":"10.1016\/j.adro.2021.100707","volume":"6","author":"JR Wilkie","year":"2021","unstructured":"Wilkie\u00a0JR, Lipson\u00a0R, Johnson\u00a0MC, Williams\u00a0C, Moghanaki\u00a0D, Elliott\u00a0D, Owen\u00a0D, Atluri\u00a0N, Jolly\u00a0S, Chapman\u00a0CH (2021) Use and outcomes of SBRT for early stage NSCLC without pathologic confirmation in the veterans health care administration. Adv Radiat Oncol 6:100707","journal-title":"Adv Radiat Oncol"},{"key":"2434_CR29","unstructured":"Leitlinienprogramm Onkologie (German Guideline Program in Oncology) (2023) S3 Guideline on Lung Cancer. https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/LL_Lungenkarzinom_Langversion_4.01_Konsultationsfassung.pdf. Accessed 7 Jan 2025"},{"key":"2434_CR30","first-page":"77","volume":"77","author":"A Takeda","year":"2012","unstructured":"Takeda\u00a0A, Kunieda\u00a0E, Sanuki\u00a0N, Aoki\u00a0Y, Oku\u00a0Y, Handa\u00a0H (2012) Stereotactic body radiotherapy (SBRT) for solitary pulmonary nodules clinically diagnosed as lung cancer with no pathological confirmation: comparison with non-small-cell lung cancer. Cancer Treat Res 77:77\u201382","journal-title":"Cancer Treat Res"},{"key":"2434_CR31","doi-asserted-by":"publisher","first-page":"720847","DOI":"10.3389\/fonc.2021.720847","volume":"11","author":"R Zhang","year":"2021","unstructured":"Zhang\u00a0R, Guo\u00a0Y, Yan\u00a0Y, Liu\u00a0Y, Zhu\u00a0Y, Kang\u00a0J, Li\u00a0F, Sun\u00a0X, Xing\u00a0L, Xu\u00a0Y (2021) A propensity-matched analysis of survival of clinically diagnosed early-stage lung cancer and biopsy-proven early-stage non-small cell lung cancer following stereotactic ablative radiotherapy. Front Oncol 11:720847","journal-title":"Front Oncol"},{"key":"2434_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1753465813512545","volume":"8","author":"YM Haidar","year":"2014","unstructured":"Haidar\u00a0YM, Rahn\u00a0DA III, Nath\u00a0S, Song\u00a0W, Bazhenova\u00a0L, Makani\u00a0S, Fuster\u00a0MM, Sandhu\u00a0AP (2014) Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation. Ther Adv Respir Dis 8:3\u201312","journal-title":"Ther Adv Respir Dis"},{"issue":"24","key":"2434_CR33","doi-asserted-by":"publisher","first-page":"00295","DOI":"10.1016\/j.prro.2024.10.010","volume":"8500","author":"LL Dover","year":"2024","unstructured":"Dover\u00a0LL, Abraham\u00a0C, Kole\u00a0AJ, Weiner\u00a0A (2024) Appropriateness Criteria for Radiation Therapy in the Setting of Presumed Early-Stage Lung Cancer. Pract Radiat Oncol 8500(24):295\u2013299. https:\/\/doi.org\/10.1016\/j.prro.2024.10.010","journal-title":"Pract Radiat Oncol"},{"key":"2434_CR34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13014-022-02183-3","volume":"17","author":"F Li","year":"2022","unstructured":"Li\u00a0F, Jiang\u00a0H, Bu\u00a0M, Mu\u00a0X, Zhao\u00a0H (2022) Dose\u2013effect relationship of stereotactic body radiotherapy in non-small cell lung cancer patients. Radiat Oncol 17:211","journal-title":"Radiat Oncol"},{"key":"2434_CR35","first-page":"291","volume":"194","author":"S Janssen","year":"2016","unstructured":"Janssen\u00a0S, Kaesmann\u00a0L, Rudat\u00a0V, Rades\u00a0D (2016) Stereotactic body radiotherapy (SBRT) with lower doses for selected patients with stage\u00a0I non-small-cell lung cancer (NSCLC). Am J Physiol 194:291\u2013294","journal-title":"Am J Physiol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02434-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-025-02434-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02434-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T11:06:25Z","timestamp":1772449585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-025-02434-8"}},"subtitle":["Pulmonary function changes, treatment-related toxicity and survival outcome"],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2434"],"URL":"https:\/\/doi.org\/10.1007\/s00066-025-02434-8","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Department of Radiation Oncology of the LMU University Hospital, LMU Munich has research agreements with Elekta, Brainlab, and C\u2011RAD outside the submitted work. E.\u00a0Degerli, K.\u00a0El-Marouk, S.\u00a0Mansoorian, C.\u00a0Richlitzki, D.\u00a0Kauffmann-Guerrero, T.\u00a0Duell, N.-S.\u00a0Schmidt-Hegemann, A.\u00a0Tufman and K.\u00a0Khaltar declare that they have no competing interests related to this manuscript. A.\u00a0Tufman receives travel support from Pfizer and Amgen. F.\u00a0Manapov receives honoraria from AstraZeneca, Novartis, Roche, Lilly, Elekta and Brainlab outside the submitted work. F.\u00a0Manapov serves on the advisory board of AstraZeneca, Novartis. L.\u00a0K\u00e4smann receives an unrestricted Research Institutional Grant from AstraZeneca. L.\u00a0K\u00e4smann receives honoraria from AMGEN. C.\u00a0Belka reports receiving grants or contracts from ViewRay, Brainlab, and Elekta; payment or honoraria from Bristol-Myers Squibb, Roche, Merck, AstraZeneca, Opasca, C\u2011RAD, Elekta, and ViewRay; receiving support for attending meetings or travel from Bristol-Myers Squibb, Roche, Merck, AstraZeneca, Elekta, and ViewRay; and having a\u00a0leadership or fiduciary role with ESTRO, all outside the submitted work. N.\u00a0Reinmuth reports receiving honoraria for speaker activities and participation in advisory boards for AbbVie, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Roche, and Takeda outside the submitted work. C.\u00a0Eze reports consulting fees from AstraZeneca, Novartis outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}